Gyre Therapeutics Q4 revenue beats estimates on new product launch

Overview

• US biopharma firm's Q4 revenue rose 33% yr/yr, beating analyst expectations

• Company posted a Q4 net loss as operating expenses increased sharply

• Gyre expects 2026 revenue to decline as it prioritizes regulatory activities and moderates promotions

Outlook

• Gyre Therapeutics sees 2026 revenue between $100.5 mln and $111.0 mln

• Company expects 2026 to be a transition period with focus on regulatory activities

• Gyre expects to moderate promotional activities for Contiva and Etorel amid procurement uncertainties

Result Drivers

• NEW PRODUCT LAUNCHES - Sales from Contiva and Etorel, launched in 2025, contributed to revenue growth

• ETUARY SALES - Increased ETUARY sales attributed to strengthened commercial execution and reallocation of marketing resources

• HIGHER OPERATING EXPENSES - Sharp increase in selling, marketing, and R&D expenses offset revenue gains

Company press release: ID:nGNXbkKWrh

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Gyre Therapeutics Inc is $18.00, about 116.1% above its March 11 closing price of $8.33

• The stock recently traded at 48 times the next 12-month earnings vs. a P/E of 42 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.